Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will announce its Q2 2021 financial results on July 29, 2021, after market close. The results will be discussed in a conference call at 3 PM PT (6 PM ET). Investors can listen in by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, with a passcode of 5382265. A webcast will also be available on the company’s website under “Quarterly Results” and will remain accessible for one year. Bio-Rad, based in Hercules, California, reported revenues of over $2.5 billion in 2020.
Bio-Rad Laboratories (NYSE: BIO, BIOb) has partnered with Seegene, Inc. to develop and commercialize infectious disease molecular diagnostic products. Seegene will supply diagnostic tests for Bio-Rad's CFX96™ Dx Real-Time PCR System, pending FDA clearance. The partnership aims to enhance diagnostic testing in U.S. markets. Seegene's assays are noted for their multiplex capabilities, detecting up to seven infectious disease targets simultaneously with results available in about four hours. This collaboration aligns with Bio-Rad's mission to improve healthcare through innovative diagnostic solutions.
Bio-Rad Laboratories (NYSE: BIO, BIOb) launched the PREvalence™ ddPCR® SARS-CoV-2 Wastewater Quantification Kit, designed to accurately detect SARS-CoV-2 in wastewater, offering a cost-effective early warning system for communities. This kit can identify the virus days to weeks before individual testing, aligning with CDC recommendations. It integrates with Bio-Rad’s existing platforms, enhancing their COVID-19 product portfolio. Bio-Rad emphasizes its commitment to supporting public health amid the ongoing pandemic.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced that key executives, including President and CEO Norman Schwartz, will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 2 at noon PT. The event will provide insights into the company's strategies and initiatives. A live webcast link will be available on their Investor Relations page.
Bio-Rad Laboratories reported Q1 2021 net sales of $726.8 million, a 27.1% increase from $571.6 million in Q1 2020. Life Science segment sales rose 61.3% to $366.5 million, driven by COVID-19 product demand. Clinical Diagnostics segment sales increased 5.4% to $358.5 million. Net income surged to $977.4 million ($32.38 per share) from $685.9 million ($22.72 per share) in the previous year. The company expects 5.5% to 6.0% currency-neutral revenue growth for the year. Gross margin slightly declined to 55.1% from 55.5%.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIOb) will announce its financial results for the first quarter of 2021 on April 29, 2021, after market close. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). Investors can participate by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, using the passcode 4692298. Additionally, the call will be available live via a webcast on the company's website.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will participate in a virtual Fireside Chat at the Barclays Global Healthcare Conference on March 9 at 10:15 AM PST. Norman Schwartz (President and CEO), Andrew Last (Executive VP and COO), and Ilan Daskal (Executive VP and CFO) will represent the company. A live webcast will be accessible on their Investor Relations page at bio-rad.com.
Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, boasting over $2.5 billion in revenue in 2020 and 7,800 employees globally.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will have its leadership team, including CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal, participate in a virtual Fireside Chat at Citi's 2021 Healthcare Services conference on February 24 at 11:25 AM PST. This event highlights Bio-Rad's commitment to innovation in life science research and clinical diagnostics. With over 65 years of experience and revenues surpassing $2.5 billion in 2020, Bio-Rad continues to advance healthcare solutions globally.
Bio-Rad Laboratories reported Q4 2020 results with net sales of $789.8 million, a 26.5% increase from Q4 2019. Life Science segment sales surged 77.1% to $428.5 million, largely driven by COVID-19-related demand. Gross margin improved to 58.3% from 52.9% year-over-year. Net income soared to $839.1 million, or $27.81 per share, compared to $553.5 million, or $18.31 per share in Q4 2019. Clinical Diagnostics segment saw a 5.1% decrease in sales. The company was awarded Emergency Use Authorization for new COVID-19 tests.
Bio-Rad Laboratories will announce its financial results for Q4 and full year 2020 on February 11, 2021, post-market. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET) the same day. Investors can access the call by dialing 855-779-9068 within the U.S. or 631-485-4862 internationally, using Conference ID: 8269933. The call will also be available via a webcast on the company’s Investor Relations page, which will remain accessible for one year.